Sera Prognostics Announces 2024 Annual Meeting of Stockholders on June 6

Ticker: SERA · Form: DEF 14A · Filed: Apr 23, 2024 · CIK: 1534969

Sentiment: neutral

Topics: Proxy Statement, Annual Meeting, Director Election, Auditor Ratification, Shareholder Vote

TL;DR

<b>Sera Prognostics will hold its 2024 Annual Meeting of Stockholders online on June 6, 2024, to elect directors and ratify auditors.</b>

AI Summary

SERA PROGNOSTICS, INC. (SERA) filed a Proxy Statement (DEF 14A) with the SEC on April 23, 2024. The 2024 Annual Meeting of Stockholders for Sera Prognostics, Inc. will be held online on June 6, 2024. The meeting will include the election of three Class III directors for three-year terms ending in 2027. Stockholders will also vote to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2024. The record date for determining stockholders eligible to vote is April 10, 2024. The meeting will be conducted via live webcast at www.virtualshareholdermeeting.com/SERA2024.

Why It Matters

For investors and stakeholders tracking SERA PROGNOSTICS, INC., this filing contains several important signals. This filing is a proxy statement, indicating key corporate governance decisions are being presented to shareholders for a vote. The election of directors and ratification of auditors are standard but crucial agenda items for annual meetings, impacting the company's leadership and financial oversight.

Risk Assessment

Risk Level: low — SERA PROGNOSTICS, INC. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain new financial or operational data that would indicate significant risk.

Analyst Insight

Stockholders should review the director nominees and the ratification of the auditor to make informed voting decisions at the upcoming annual meeting.

Key Numbers

Key Players & Entities

FAQ

When did SERA PROGNOSTICS, INC. file this DEF 14A?

SERA PROGNOSTICS, INC. filed this Proxy Statement (DEF 14A) with the SEC on April 23, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by SERA PROGNOSTICS, INC. (SERA).

Where can I read the original DEF 14A filing from SERA PROGNOSTICS, INC.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by SERA PROGNOSTICS, INC..

What are the key takeaways from SERA PROGNOSTICS, INC.'s DEF 14A?

SERA PROGNOSTICS, INC. filed this DEF 14A on April 23, 2024. Key takeaways: The 2024 Annual Meeting of Stockholders for Sera Prognostics, Inc. will be held online on June 6, 2024.. The meeting will include the election of three Class III directors for three-year terms ending in 2027.. Stockholders will also vote to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2024..

Is SERA PROGNOSTICS, INC. a risky investment based on this filing?

Based on this DEF 14A, SERA PROGNOSTICS, INC. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting and does not contain new financial or operational data that would indicate significant risk.

What should investors do after reading SERA PROGNOSTICS, INC.'s DEF 14A?

Stockholders should review the director nominees and the ratification of the auditor to make informed voting decisions at the upcoming annual meeting. The overall sentiment from this filing is neutral.

How does SERA PROGNOSTICS, INC. compare to its industry peers?

Sera Prognostics operates in the medical laboratories industry, focusing on prognostic tests.

Are there regulatory concerns for SERA PROGNOSTICS, INC.?

This filing is made under Section 14(a) of the Securities Exchange Act of 1934, which governs the solicitation of proxies.

Industry Context

Sera Prognostics operates in the medical laboratories industry, focusing on prognostic tests.

Regulatory Implications

This filing is made under Section 14(a) of the Securities Exchange Act of 1934, which governs the solicitation of proxies.

What Investors Should Do

  1. Review the biographies and qualifications of the director nominees.
  2. Evaluate the rationale for ratifying Ernst & Young LLP as the independent auditor.
  3. Ensure voting rights are exercised by the record date of April 10, 2024.

Key Dates

Year-Over-Year Comparison

This is a DEF 14A filing, which is a definitive proxy statement for an annual meeting, indicating a routine corporate governance event rather than a new financial disclosure.

Filing Stats: 4,825 words · 19 min read · ~16 pages · Grade level 12.1 · Accepted 2024-04-23 16:06:10

Filing Documents

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 35 General Compensation Philosophy and Process for Compensation Decisions 35 Summary Compensation Table 35 Narrative Disclosure to Summary Compensation Table 36 Base Salaries 36 Non-Equity Incentive Compensation Plan 36 Equity Compensation 37 Employment Arrangements 37 Severance and Change of Control Benefits 38 Outstanding Equity Awards at December 31, 2023 39 Equity Compensation Plan Information 41 401(k) Plan 41 4 Pension Benefits 41 Nonqualified Deferred Compensation 41 Compensation Committee Interlocks and Insider Participation 41 Prohibition on Hedging and Pledging 42 Conclusion 42

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 43 CERTAIN RELATIONSHIPS, RELATED PARTY AND OTHER TRANSACTIONS 46 Policies and Procedures for Related Party Transactions 46 Agreements with Stockholders 46 Elevance Health Commercialization Agreement 46 Elevance Health Laboratory Services Agreement 46 Baker Bros . Side Letter 46 Vivo Management Rights Letter 47 Investors' Rights Agreement 47 Indemnification Agreements 48 Other Transactions 48 OTHER MATTERS 49 2023 Annual Report and SEC Filings 49 Incorporation by Reference 49 Stockholder Proposals and Nominations for Director 49 Other Matters 49 5 SERA PROGNOSTICS, INC. 2749 East Parleys Way, Suite 200 Salt Lake City, Utah 84109 PROXY STATEMENT FOR 2024 ANNUAL MEETING OF STOCKHOLDERS to be held on Thursday, June 6, 2024 at 800 a.m. Mountain Time This proxy statement, along with the accompanying notice of 2024 Annual Meeting of Stockholders, contains information about the 2024 Annual Meeting of Stockholders of Sera Prognostics, Inc., including any adjournments or postponements of the annual meeting. We are holding the 2024 Annual Meeting at 800 a.m. Mountain Time, on Thursday, June 6, 2024. We have decided to hold this year's meeting virtually via live webcast on the Internet because hosting a virtual annual meeting enables greater stockholder attendance and participation from any location around the world, improves meeting efficiency and our ability to communicate effectively with our stockholders, and reduces the cost and environmental impact of our annual meeting. You will be able to attend our annual meeting, vote and submit your questions during the meeting by visiting www.virtualshareholdermeeting.comSERA2024. You will not be able to attend the annual meeting in person. In this proxy statement, we refer to Sera Prognostics, Inc. as "the Company," "we," and "us." This proxy statement relates to the solicitation of proxies by our board of direc

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing